Cargando…

Informing virtual clinical trials of hepatocellular carcinoma with spatial multi-omics analysis of a human neoadjuvant immunotherapy clinical trial

Human clinical trials are important tools to advance novel systemic therapies improve treatment outcomes for cancer patients. The few durable treatment options have led to a critical need to advance new therapeutics in hepatocellular carcinoma (HCC). Recent human clinical trials have shown that new...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shuming, Deshpande, Atul, Verma, Babita K., Wang, Hanwen, Mi, Haoyang, Yuan, Long, Ho, Won Jin, Jaffee, Elizabeth M., Zhu, Qingfeng, Anders, Robert A., Yarchoan, Mark, Kagohara, Luciane T., Fertig, Elana J., Popel, Aleksander S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462044/ https://www.ncbi.nlm.nih.gov/pubmed/37645761 http://dx.doi.org/10.1101/2023.08.11.553000

Ejemplares similares

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
por: Zhang, Shuming, et al.
Publicado: (2023)

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
por: Zhang, Shuming, et al.
Publicado: (2023)

Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
por: Sové, Richard J, et al.
Publicado: (2022)

Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response
por: Zhang, Shuming, et al.
Publicado: (2021)

Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy
por: Ho, Won Jin, et al.
Publicado: (2020)

Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors
por: Wang, Hanwen, et al.
Publicado: (2020)

Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer
por: Mi, Haoyang, et al.
Publicado: (2020)

Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials
por: Sidiropoulos, Dimitrios N., et al.
Publicado: (2022)

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma
por: Mi, Haoyang, et al.
Publicado: (2022)

Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes
por: Fertig, Elana J., et al.
Publicado: (2015)

Systems biology of angiogenesis signaling: Computational models and omics
por: Zhang, Yu, et al.
Publicado: (2021)

Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma
por: Jafarnejad, Mohammad, et al.
Publicado: (2019)

Generating colorblind-friendly scatter plots for single-cell data
por: Guha, Tejas, et al.
Publicado: (2022)

Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis
por: Lee, Esak, et al.
Publicado: (2014)

Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance
por: Stein-O’Brien, Genevieve, et al.
Publicado: (2018)

Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade
por: Shu, Daniel H., et al.
Publicado: (2023)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
por: Ho, Won Jin, et al.
Publicado: (2021)

Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA
por: Izumchenko, Evgeny, et al.
Publicado: (2015)

Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition
por: Wang, Hanwen, et al.
Publicado: (2023)

Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition
por: Wang, Hanwen, et al.
Publicado: (2023)

Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
por: Kagohara, Luciane T., et al.
Publicado: (2020)

Correction: Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
por: Kagohara, Luciane T., et al.
Publicado: (2020)

Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture
por: Mi, Haoyang, et al.
Publicado: (2021)

Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy
por: Li, Keyu, et al.
Publicado: (2022)

Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers
por: Mi, Haoyang, et al.
Publicado: (2022)

A Software Application for Mining and Presenting Relevant Cancer Clinical Trials per Cancer Mutation
por: Gandy, Lisa M, et al.
Publicado: (2017)

Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model
por: Ruiz-Martinez, Alvaro, et al.
Publicado: (2022)

Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways
por: Ho, Won Jin, et al.
Publicado: (2021)

In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model
por: Wang, Hanwen, et al.
Publicado: (2019)

A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy
por: Bigelow, Emma, et al.
Publicado: (2022)

Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials
por: Witt, Russell G., et al.
Publicado: (2022)

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
por: Chan, T A, et al.
Publicado: (2019)

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
por: Diehl, Adam, et al.
Publicado: (2017)

Criteria for the use of omics-based predictors in clinical trials
por: McShane, Lisa M., et al.
Publicado: (2013)

Epigenetic regulation of gene expression in cancer: techniques, resources and analysis
por: Kagohara, Luciane T, et al.
Publicado: (2017)

Quantifying Intratumoral Heterogeneity and Immunoarchitecture Generated In-Silico by a Spatial Quantitative Systems Pharmacology Model
por: Nikfar, Mehdi, et al.
Publicado: (2023)

The Advent of Omics Sciences in Clinical Trials of Motor Neuron Diseases
por: Ruffo, Paola, et al.
Publicado: (2022)

Extracellular Vesicles Released by Tumor Endothelial Cells Spread Immunosuppressive and Transforming Signals Through Various Recipient Cells
por: Lopatina, Tatiana, et al.
Publicado: (2020)

Digitizing omics profiles by divergence from a baseline
por: Dinalankara, Wikum, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_blek5jqcnc27ht5v8llgevqop5